All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
On the 3rd of October 2019 the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for duvelisib as a treatment for patients with T-cell lymphoma in addition to the previously-granted Fast Track status, for peripheral T-Cell lymphoma.1
Duvelisib, is an oral inhibitor of phosphoinositide 3-kinase (PI3K)-δ and PI3K-γ, enzymes involved in pathways supporting the growth and survival of malignant B-cells, as well as the formation and maintenance of the tumor microenvironment.
The drug has been previously approved for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies and accelerated approval in follicular lymphoma (FL) after at least two prior systemic therapies. The phase II PRIMO study of duvelisib monotherapy in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) is currently ongoing and will provide further data on dosing regimen, efficacy and safety.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox